Macclesfield, United Kingdom

Thomas Pesnot


 

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Chester, GB (2022)
  • Macclesfield, GB (2022 - 2024)

Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: The Innovative Contributions of Thomas Pesnot

Introduction

Thomas Pesnot is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific protein kinases. With a total of five patents to his name, Pesnot's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, Pesnot has developed modulators of rho-associated protein kinase. This invention relates to novel compounds and pharmaceutical compositions that comprise these compounds. The compounds are useful as modulators of Rho-associated protein kinase (ROCK), specifically as inhibitors of ROCK1 and/or ROCK2. Methods of treatment employing these compounds are also contemplated by the present invention. The compounds are particularly useful in treating diseases mediated by ROCK.

Career Highlights

Throughout his career, Thomas Pesnot has worked with prominent companies in the pharmaceutical industry. Notable among these are Redx Pharma Limited and Bayer Aktiengesellschaft. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Pesnot has collaborated with several professionals in his field, including Peter Bunyard and Gary Pitt. These collaborations have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Thomas Pesnot's innovative work in the field of pharmaceutical sciences demonstrates his commitment to advancing medical treatments. His patents on modulators of rho-associated protein kinase highlight the potential for new therapies in addressing ROCK-mediated diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…